November 27 Product: Orphan Pharmaceuticals Rapiblyk Indication: Atrial fibrillation and atrial flutter in critical care Vienna-based AOP Orphan Pharmaceuticals on Wednesday won the FDAs approval for Rapiblyk (landiolol) for the treatment of atrial fibrillation and atrial flutter in the critical care setting
Formulated with 0.9% benzyl alcohol, each vial stays sterile and stable for up to 28 days after first use giving you reliable, multi-dose access without compromising purity
Cancers are part of a complex ecosystem, the body. GLP-1 drugs may tweak the immune system in a way that boosts its cancer-fighting aspects, such as T-cells, and dampens inflammation, which helps tumors thrive
Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex
But breakfast is a critical nutritional touchpoint
The drug carries risks of some serious side effects, especially when used alongside certain other medical conditions or before pregnancy